37215壓力測(cè)試儀是經(jīng)典的7200 paw壓力測(cè)試儀的升級(jí)產(chǎn)品，自1965年S次使用以來(lái)，該測(cè)試儀在多個(gè)學(xué)術(shù)和工業(yè)實(shí)驗(yàn)室為鎮(zhèn)痛藥物的開(kāi)發(fā)和研究做出了貢獻(xiàn)。
 

壓痛儀的主要特點(diǎn)：

· 提供三種測(cè)試量程：250g，500g，750g

· 簡(jiǎn)單可靠：無(wú)需校準(zhǔn)！

· 標(biāo)準(zhǔn)為砝碼測(cè)試型號(hào)，可根據(jù)需要選擇數(shù)字顯示型號(hào)；

· 提供小鼠專用型號(hào)，測(cè)量更準(zhǔn)確；

· 1960年代以來(lái)的經(jīng)典方法：發(fā)表論文數(shù)百篇！

型號(hào)：37215型

· 爪子放置在帶有圓形JD的錐形推動(dòng)器下方的小底座上；

· 操作人員按下踏板開(kāi)關(guān)，壓力由小到大施加到動(dòng)物的爪子上；

· 力以恒定速率增加，使得測(cè)試具備很好的可重復(fù)性；

· 動(dòng)物感受到疼痛時(shí)會(huì)產(chǎn)生躲避反應(yīng)；

· 松開(kāi)踏板開(kāi)關(guān)，壓力立即停止；

· 在以10g為步進(jìn)單位施加力；

· 采用低壓同步電機(jī)，符合CE規(guī)則；

· 根據(jù)需要，可選擇小鼠專用的型號(hào)；

· 數(shù)顯型號(hào)更容易記錄數(shù)據(jù)和讀取數(shù)據(jù)；

· 傳統(tǒng)款式和數(shù)顯款式采用箱體的測(cè)試結(jié)構(gòu)，測(cè)量數(shù)據(jù)一致；

· 數(shù)字顯示器采用模塊化設(shè)計(jì)，可以對(duì)傳統(tǒng)款式進(jìn)行升級(jí)；

37215型壓痛儀的主要規(guī)格
· 電源：115或230V，50/60Hz

· 功率：15W
· 操控方式：踏板開(kāi)關(guān)

· 尺寸：40 x 16 x 14cm
· 重量：2.1Kg
 

型號(hào)和測(cè)試量程
· 37215，大鼠小鼠通用型：250g，500g，750g
· 37216，小鼠型號(hào)：125g，250g，375g

壓力模塊

參考文獻(xiàn)：

1.Baloh, Robert H et al. “Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.” Nature 

medicine vol. 28,9 (2022): 1813-1822. doi:10.1038/s41591-022-01956-3

2.Bosse, Gabriel D et al. “The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.” The Journal of clinical 

investigation vol. 131,10 (2021): e143990. doi:10.1172/JCI143990

3.Bang, Sangsu et al. “GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain.” The Journal of clinical investigation vol. 128,8 (2018): 

3568-3582. doi:10.1172/JCI99888

4.Goebel, Andreas et al. “Passive transfer of fibromyalgia symptoms from patients to mice.” The Journal of clinical investigation vol. 131,13 (2021): e144201. 

doi:10.1172/JCI144201

5.Sikandar, Shafaq et al. “Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain.” Brain : a journal of neurology vol. 141,4 

(2018): 1028-1039. doi:10.1093/brain/awy009

6.Vidal-Torres, Alba et al. “Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and 

safety profile compared to strong opioids.” Acta pharmaceutica Sinica. B vol. 13,1 (2023): 82-99. doi:10.1016/j.apsb.2022.09.018

7.Mousa, Shaaban A et al. “Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain 

areas.” Journal of neuroinflammation vol. 19,1 148. 15 Jun. 2022, doi:10.1186/s12974-022-02498-8

8.Zhou, Danli et al. “Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain.” Journal of 

neuroinflammation vol. 16,1 83. 11 Apr. 2019, doi:10.1186/s12974-019-1476-6

9.Wang, Wenying et al. “Exchange factor directly activated by cAMP-PKCε signalling mediates chronic morphine-induced expression of purine P2X3 receptor in rat 

dorsal root ganglia.” British journal of pharmacology vol. 175,10 (2018): 1760-1769. doi:10.1111/bph.14191

10.Sala, Emanuele et al. “Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent 

models.” British journal of pharmacology vol. 177,14 (2020): 3291-3308. doi:10.1111/bph.15049